Skip to main content
Equibles
CYDY logo

CYDY · CytoDyn Inc. · Metrics

Track CYDY — free

Use CYDY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CYDY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.25 +0.00 (+0.04%) At close · Oct 20
Rebalance outlook locked
Going-concern doubt — flagged Oct 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company had an accumulated deficit of approximately $950.4 million as of August 31, 2026. These factors, among several others, raise substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Oct 14, 2026
Market Cap
$367.38M
Shares
1.47B
Volume · Oct 20 7.35M Avg daily vol (3M) 1.68M

CYDY metrics

64 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.25
Market cap
$367.38M

Price action

20 metrics
Price change (1W)
+25.7%
Price change (30D)
+13.7%
Price change (3M)
+25.1%
Price change (6M)
-32.4%
Price change (YTD)
-10.7%
Price change (1Y)
-3.8%
Trailing year
Price change (5Y)
-83.3%
52-week high
$0.37
52-week low
$0.19
Change from 52-week high
-32.4%
Change from 52-week low
+34.1%
Annualized volatility
65.7%
Annualized volatility (3M)
61.8%
Beta
0.5
RSI (14D)
73.7
Price vs SMA 50
+19.8%
Price vs SMA 200
-1.4%
Avg volume (3M)
1.68M
Relative volume
4.4
Average dollar volume
$352,275

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.47B

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-15.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
30.4×
reciprocal yield 3.3%
EV / EBIT historical average (5Y)
30.4×
reciprocal yield 3.3%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$40.21M
Net income (TTM)
−$57.09M
Trailing 12 months
Diluted EPS (TTM)
$-0.04
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.03
EBITDA per diluted share (TTM)
$-0.03
Net income per diluted share (TTM)
$-0.04
Operating cash flow per diluted share (TTM)
$-0.02
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.01
Stock compensation per diluted share (TTM)
$0.00
Book value per share
$-0.08

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
-1,240.2%
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+10.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-299.6%
Debt / equity
—
Current ratio
0.4
EBITDA (TTM)
−$40.17M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$19.45M
Latest balance sheet
Cash & equivalents
$16.36M
Total assets
$19.05M
Total debt
$35.81M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$22.53M
Capital expenditures (TTM)
$52,000
R&D (TTM)
$7.24M
SG&A (TTM)
—
Stock compensation (TTM)
$1.98M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
6
13F filer change QoQ
-3
Institutional ownership
0.0%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
-53.6%
Holder tenure
15.2
Price vs estimated holder cost
-86.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
2.5%
Latest settlement · 11.5 days to cover
Days to cover
11.5d
Short-squeeze score
85 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1175680 CUSIP 23283M101 13F (30d) 1 filings 1 filers Visit website Investor relations